

Haematologica  
HAEMATOL/2016/142190  
Version 4

Newly established myeloma-derived stromal cell line MSP-1 supports Multiple Myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma

Pilar de la Puente, Nancy Quan, Ryan Soo Hoo, Barbara Muz, Rebecca C. Gilson, Micah Luderer, Justin King, Samuel Achilefu, Noha Nabil Salama, Ravi Vij, and Abdel Kareem Azab

Disclosures: This research was partially supported by the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and the National Cancer Institute of the NIH under Award Number U54CA199092. Conflict of interest: Dr. Azab receives research support from Verastem, Selexys, Karyopharm, Cell Works, Cleave Bioscience, Glycomimetics, Abbvie and Seattle Genetics; and is the founder and owner of Targeted Therapeutics LLC and Cellatrix LLC. Dr. de la Puente is co-founder of Cellatrix LLC. Other authors state no conflicts of interest. Patents: Dr. de la Puente and Dr. Azab have a provisional patent application on the 3DTEBM method described in this manuscript, and an invention disclosure has been filed with the MSP1 cell line.

Contributions: Contribution: P.P. designed the study, performed experiments, analyzed, interpreted the data and wrote the manuscript; N.Q., R. S., and R.G., performed research and analyzed data; B.M., M.L, S.A., analyzed and interpreted data; J.K. and R.V., provided primary samples, analyzed and interpreted data; A.K.A., designed and supervised the study, interpreted the data and edited the manuscript. All authors reviewed and approved the manuscript.